• ABT-199 (Venetoclax): Redefining Apoptosis in Hematologic Re

  2026-07-16

  This article explores how ABT-199 (Venetoclax) is transforming the field of apoptosis research in hematologic malignancies. By combining mechanistic insights with strategic recommendations for translational research, we highlight how selective Bcl-2 inhibition unlocks new experimental and clinical opportunities. The discussion integrates fresh findings on apoptosis pathways, competitive landscape analysis, and actionable workflow parameters, while positioning ABT-199 from APExBIO as the benchmark tool for next-generation apoptosis assays.

• Plerixafor (AMD3100): Applied Workflows and Troubleshooting

  2026-07-16

  Plerixafor (AMD3100) is the gold-standard CXCR4 antagonist, empowering both cancer and stem cell researchers to dissect and manipulate the SDF-1/CXCR4 axis. This guide translates recent experimental insights into actionable protocols, troubleshooting steps, and advanced use-cases to help you maximize reproducibility and translational impact.

• Targeting FLT3-TAZ Signaling to Overcome Drug Resistance in

  2026-07-15

  Shin et al. (2023) identify FLT3-driven signaling as a key mechanism underlying broad drug resistance in blast phase chronic myeloid leukemia (BP-CML), establishing FLT3 as a novel prognostic marker and therapeutic target. Their work demonstrates that inhibiting FLT3—alone or in combination with BCR::ABL1 TKIs—can suppress resistance, suggesting promising new directions for high-risk BP-CML treatment.

• TBST (Tris-Buffered Saline and Tween 20): Technical Lab Use

  2026-07-15

  TBST (Tris-Buffered Saline and Tween 20) addresses high background and nonspecific binding in immunoassays by providing a reliable, isotonic blocking and washing buffer. It is recommended for workflows such as Western blotting, immunofluorescence, and immunohistochemistry, but should not be used in applications sensitive to non-ionic detergents.

• DRD4 Drives Chemo-Resistance via PI3K/Akt/β-Catenin in Liver

  2026-07-14

  The reference study demonstrates that dopamine receptor D4 (DRD4) promotes chemo-resistance and cancer stem cell-like properties in hepatocellular carcinoma by activating the PI3K/Akt/β-catenin axis. These findings highlight DRD4 as a potential therapeutic target and underscore the relevance of PI3K pathway inhibitors in overcoming resistance in liver cancer models.

• FK866 (APO866): Advanced Workflows in Hematologic Cancer Res

  2026-07-14

  FK866 (APO866) empowers researchers to probe NAD metabolism and selective cytotoxicity in hematologic cancers with nanomolar precision. Discover rigorous protocol guidance, troubleshooting strategies, and translational applications that set APExBIO’s FK866 apart for acute myeloid leukemia and combination therapy studies.

• Drug-Sensitized Yeast System for mTOR Inhibitor Discovery

  2026-07-13

  This study introduces a highly sensitive yeast-based screening platform for identifying mTOR inhibitors, leveraging drug-sensitized strains to enhance detection of TOR pathway inhibition. The approach significantly increases sensitivity to known inhibitors, enabling rapid, cost-effective compound screening crucial for geroprotective and oncology research.

• Aconitase Activity Colorimetric Assay Kit: Applied Workflows

  2026-07-13

  The Aconitase Activity Colorimetric Assay Kit from APExBIO empowers precise, rapid quantification of iron-sulfur protein aconitase across diverse biological samples. This article sheds light on experimental best practices, troubleshooting strategies, and real-world applications in oxidative stress and immunometabolic research.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-07-12

  This study identifies the WNT5a/GSK3/β-catenin signaling axis as a central regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological, cytometric, and transcriptomic approaches, the authors demonstrate that modulating this pathway can restrain fat infiltration in muscle, highlighting new strategies for muscle regeneration and myopathy research.

• Dasatinib Monohydrate in CML Research: Advanced Workflows &

  2026-07-10

  Dasatinib Monohydrate (BMS-354825) sets a new standard for precision targeting in chronic myeloid leukemia research, especially where imatinib resistance is a challenge. Explore actionable protocols, troubleshooting essentials, and translational findings that maximize the impact of this multitargeted kinase inhibitor in both classic and cutting-edge assay systems.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody: Practic

  2026-07-09

  The HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides sensitive, specific fluorescent detection of rabbit primary antibodies in immunofluorescence, microscopy, and flow cytometry workflows. It is best used in protocols requiring robust signal amplification and is unsuitable for detecting non-rabbit primaries or in workflows incompatible with its storage buffer components.

• Brassinolide: Translational Power from Plant Biology to Canc

  2026-07-09

  This thought-leadership article explores Brassinolide’s dual role as a pivotal plant growth regulator and as a mechanistically defined apoptosis inducer in translational cancer and diabetes research. We synthesize recent advances in biosynthetic structure–activity relationships, highlight best-practice assay design, and provide strategic guidance for researchers seeking robust, reproducible results with Brassinolide (24-Epibrassinolide). By bridging plant biology and human disease models—anchored by peer-reviewed evidence and the latest analog benchmarking—this article delivers actionable insights beyond standard product guides.

• TBK1 Inhibition Mitigates Painful Diabetic Neuropathy via Mi

  2026-07-08

  Liao et al. (2024) elucidate the mechanistic link between TANK-binding kinase 1 (TBK1) activation in spinal microglia and the development of painful diabetic neuropathy (PDN) through pyroptosis. Their findings show that targeting TBK1, via siRNA or pharmacological inhibitors, attenuates neuropathic pain and neuroinflammation, highlighting TBK1 as a promising therapeutic target for PDN.

• NF 449 Reveals P2X1-Dependent Platelet Activation Mechanisms

  2026-07-08

  The reference study establishes NF 449 as a highly selective purinergic receptor antagonist, providing direct evidence that P2X1 channels contribute to platelet activation and thrombus formation. These findings clarify P2 receptor subtype functions and support NF 449 as a tool for dissecting platelet aggregation pathways relevant to antithrombotic research.

• Crizotinib Hydrochloride in Assembloid Models: Empowering Tr

  2026-07-07

  This in-depth article explores how Crizotinib hydrochloride, a potent ALK kinase inhibitor, is transforming translational cancer research—especially within patient-derived gastric cancer assembloid models. It integrates mechanistic insights, protocol strategies, and translational guidance, while highlighting recent advances in physiologically relevant drug screening and resistance profiling. Drawing on the latest assembloid literature, this piece demonstrates the strategic value of APExBIO's Crizotinib hydrochloride (SKU B3608) for researchers seeking to bridge mechanistic discovery and clinically relevant modeling.

14629 records 1/976 page Next 12345 下5页 Last page